Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk Ventilation 40% Ventilation (b) 50% ICU admission 27% ICU admission (b) 30% c19early.org/c Hess et al. Vitamin C for COVID-19 LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? Retrospective 100 patients in the USA (March - July 2020) Lower mortality (p=0.54) and ICU admission (p=0.11), not stat. sig. Hess et al., Internal and Emergency Medicine, doi:10.1007/s11739-022-02954-6 Favors vitamin C Favors control
High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID-19
Hess et al., Internal and Emergency Medicine, doi:10.1007/s11739-022-02954-6
Hess et al., High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe.., Internal and Emergency Medicine, doi:10.1007/s11739-022-02954-6
Mar 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 100 severe condition hospitalized patients in the USA, 25 treated with high dose IV vitamin C, showing lower mechanical ventilation and cardiac arrest, and increased length of survival with treatment. 3g IV vitamin C every 6h for 7 days.
risk of death, 20.0% lower, HR 0.80, p = 0.54, treatment 10 of 25 (40.0%), control 37 of 75 (49.3%), NNT 11, time to event analysis, propensity score weighting.
risk of mechanical ventilation, 39.5% lower, RR 0.60, p = 0.0499, treatment 18 of 25 (72.0%), control 54 of 75 (72.0%), odds ratio converted to relative risk, propensity score weighting.
risk of mechanical ventilation, 50.0% lower, HR 0.50, p = 0.03, treatment 18 of 25 (72.0%), control 54 of 75 (72.0%), time to event analysis, propensity score weighting.
risk of ICU admission, 27.2% lower, RR 0.73, p = 0.10, treatment 22 of 25 (88.0%), control 63 of 75 (84.0%), odds ratio converted to relative risk, propensity score weighting.
risk of ICU admission, 30.0% lower, HR 0.70, p = 0.19, treatment 22 of 25 (88.0%), control 63 of 75 (84.0%), time to event analysis, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hess et al., 29 Mar 2022, retrospective, USA, peer-reviewed, 9 authors, study period March 2020 - July 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Abstract: Internal and Emergency Medicine https://doi.org/10.1007/s11739-022-02954-6 EM - ORIGINAL High‑dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID‑19 Andrea L. Hess1 · Alexandra Halalau1,2 · Jonathan J. Dokter1 · Tania S. Paydawy3 · Patrick Karabon4 · Aveh Bastani1,5 · Rebecca E. Baker3 · Abdalla Kara Balla2 · Stephen A. Galens1,6 Received: 30 March 2021 / Accepted: 22 February 2022 © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022 Abstract Intravenous vitamin C (IV-VitC) has been suggested as a treatment for severe sepsis and acute respiratory distress syndrome; however, there are limited studies evaluating its use in severe COVID-19. Efficacy and safety of high-dose IV-VitC (HDIVC) in patients with severe COVID-19 were evaluated. This observational cohort was conducted at a single-center, 530 bed, community teaching hospital and took place from March 2020 through July 2020. Inverse probability treatment weighting (IPTW) was utilized to compare outcomes in patients with severe COVID-19 treated with and without HDIVC. Patients were enrolled if they were older than 18 years of age and were hospitalized secondary to severe COVID-19 infection, indicated by an oxygenation index < 300. Primary study outcomes included mortality, mechanical ventilation, intensive care unit (ICU) admission, and cardiac arrest. From a total of 100 patients enrolled, 25 patients were in the HDIVC group and 75 patients in the control group. The average time to death was significantly longer for HDIVC patients (P = 0.0139), with an average of 22.9 days versus 13.7 days for control patients. Patients who received HDIVC also had significantly lower rates of mechanical ventilation (52.93% vs. 73.14%; ­ORIPTW = 0.27; P = 0.0499) and cardiac arrest (2.46% vs. 9.06%; ­ORIPTW = 0.23; P = 0.0439). HDIVC may be an effective treatment in decreasing the rates of mechanical ventilation and cardiac arrest in hospitalized patients with severe COVID-19. A longer hospital stay and prolonged time to death may suggest that HDIVC may protect against clinical deterioration in severe COVID-19. Keywords Ascorbic acid · Vitamin C · Treatment · Intensive care · SARS-CoV-2
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit